STOCK TITAN

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

HAYWARD, Calif.--(BUSINESS WIRE)--

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and immune diseases, announced that its management team will participate in the following upcoming investor conferences in December:

8th Annual Evercore Healthcare Conference
Date: Tuesday, December 1st, 2026
Location: Coral Gables, FL
Format: Fireside chat & 1x1 meetings
Time: 3:50 p.m. ET

Citi’s 2026 Global Healthcare Conference
Date: Wednesday, December 2nd, 2026
Location: Miami, FL
Format: Fireside chat & 1x1 meetings
Time: 2:20 p.m. ET

Live webcasts of the fireside chats will be available by visiting the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com. Replays will be available following the live event.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases. Founded in 2015, Arcus pairs proven biology with exceptional chemistry to create medicines that deliver meaningful improvements for patients. The company has advanced two oncology programs to Phase 3 clinical trials, including casdatifan, a HIF-2α inhibitor for clear cell renal cell carcinoma, and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer. Arcus is also applying its small-molecule, medicinal chemistry and antibody capabilities to expand into immunology. Every program is held to the highest standard: outperform the current standard of care. For more information about Arcus Biosciences' clinical and preclinical programs, please visit www.arcusbio.com.

Investor Inquiries
Pia Eaves
VP of Investor Relations & Strategy
(617) 459-2006
peaves@arcusbio.com

Media Inquiries
Holli Kolkey
VP of Corporate Affairs
(650) 922-1269
hkolkey@arcusbio.com

Maryam Bassiri
Director, Corporate Affairs
(510) 406-8520
mbassiri@arcusbio.com

Source: Arcus Biosciences

Keep reading